Global M&A Intelligence Report 2023 – Life Sciences Supplement

This report provides an insight into life sciences M&A deal activity in 2022 and supplements our 2023 global M&A intelligence report, which is now in its ninth edition.

The life sciences sector is broad and captures a number of sub-sectors, including pharmaceutical, medical devices and biotech.

The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.

The report focuses on five key themes:

• Due Diligence (DD)
• Warranty and Indemnity (W&I) insurance
• Transaction structures 
• Trade v Private Equity 
• US v Rest of the World (RoW)